Application of in vitro and in silico tecniques in Sars-CoV-2 drug discovery
Given the impact of the pandemic caused by Sars-CoV-2 and the need for a drug to combat it, we selected a strategic protein of the virus as a druggable target. The experimental work starts with a model molecule and an open access library of different crystals of the Sars-CoV-2 MPro. Applying different bioinformatics techniques, we selected molecules, purchased and performed in vitro experiments in Brazilian labs. The result was a detailed study of the chemical environment of relevant and sensitive regions for the maintenance of the three-dimensional structure of the native enzyme and the proposal of a next generation of molecules for the treatment of COVID-19, employing the technique of vector growth of model molecules, within the context of fragment based drug Discovery (FBDD). The differential of this work compared to other studies focused on the inhibition of MPro, was the choice of the Main Protease dimerization site as a pharmacological target, given its high degree of evolutionary conservation in relation to the rest of the enzyme, thus, the drug to be developed may not only be effective for SARS-CoV-2, but may continue to serve as a treatment for new coronavirus variants that emerge over time.